Literature DB >> 18458957

Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome.

Hélène Lapillonne1, Annelaure Leclerc, Tim Ulinski, Laurent Balu, Arnaud Garnier, Nathalie Dereuddre-Bosquet, Hervé Watier, Marie-Hélène Schlageter, Georges Deschênes.   

Abstract

Steroid-sensitive nephrotic syndrome (SSNS) is classically thought to be a T-cell disorder. The aim of this study was to examine whether or not thymus homeostasis was affected in SSNS. Mature and naive T cell recent thymic emigrants were quantified in the peripheral blood of nephrotic patients and controls. Because the generation of new T cells by the thymus ultimately depends on hematopoietic stem cells, CD34+ cells were also included in the study. Nineteen patients with SSNS during relapse, 13 with SSNS during proteinuria remission, and 18 controls were studied. Cell-surface markers (CD3, CD4, CD8, CD19, CD16, CD56, CD45RA, CD62L, CD34, and CD38) were analyzed by flow cytometric analysis. T-cell rearrangement excision circles (TRECs) were quantified in CD2+ cells by real-time polymerase chain reaction. Stroma cell-derived factor-1 (SDF-1) genotype and metalloproteinase-9 (MMP-9) plasma levels were also determined. Mature T cells (CD4+ and CD8+), circulating naive T cells (CD62L+ and CD3+ CD62L+), and recent thymic emigrants (CD45RA+) as well as TRECs, that measure thymus production, had a similar level in the three groups of patients. Conversely, CD34+ hematopoietic stem cells displayed a two-fold increase in SSNS patients during relapse either compared with controls or SSNS patients at remission. In addition, compared with controls, SSNS patients at remission displayed (1) a decrease in CD19+ cells (B cells) and (2) an increase in CD16CD56+ cells [natural killer (NK) cells]. In conclusion, thymus homeostasis is not significantly affected in nephrotic patients. Hematopoietic stem-cell mobilization at proteinuria relapse, as well as changes in B and NK cells during remission, suggest that SSNS might be due to a general disturbance of hematopoietic and immune cell trafficking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458957     DOI: 10.1007/s00467-008-0793-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

Review 1.  Mycophenolate mofetil and its mechanisms of action.

Authors:  A C Allison; E M Eugui
Journal:  Immunopharmacology       Date:  2000-05

2.  Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease.

Authors:  Anna A Colombo; Chiara Rusconi; Ciro Esposito; Paolo Bernasconi; Daniela Caldera; Mario Lazzarino; Emilio P Alessandrino
Journal:  Transplantation       Date:  2006-04-27       Impact factor: 4.939

3.  Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.

Authors:  Olivier Benveniste; Antoine Flahault; Florence Rollot; Carole Elbim; Jérôme Estaquier; Béatrice Pédron; Xavier Duval; Nathalie Dereuddre-Bosquet; Pascal Clayette; Ghislaine Sterkers; Anne Simon; Jean-Claude Ameisen; Catherine Leport
Journal:  J Infect Dis       Date:  2005-04-05       Impact factor: 5.226

4.  T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome.

Authors:  Hicham Mansour; Lydie Cheval; Jean-Marc Elalouf; Jean-Christophe Aude; Maria-Alexandra Alyanakian; Béatrice Mougenot; Alain Doucet; Georges Deschênes
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

5.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)

Authors:  C Winkler; W Modi; M W Smith; G W Nelson; X Wu; M Carrington; M Dean; T Honjo; K Tashiro; D Yabe; S Buchbinder; E Vittinghoff; J J Goedert; T R O'Brien; L P Jacobson; R Detels; S Donfield; A Willoughby; E Gomperts; D Vlahov; J Phair; S J O'Brien
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

6.  Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome.

Authors:  J Dantal; Y Godfrin; R Koll; S Perretto; J Naulet; J F Bouhours; J P Soulillou
Journal:  J Am Soc Nephrol       Date:  1998-09       Impact factor: 10.121

7.  Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome.

Authors:  M J Kemper; T Meyer-Jark; M Lilova; D E Müller-Wiefel
Journal:  Clin Nephrol       Date:  2003-10       Impact factor: 0.975

8.  A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells.

Authors:  Anne-Laure Sellier-Leclerc; Arnaud Duval; Stéphanie Riveron; Marie-Alice Macher; Georges Deschenes; Chantal Loirat; Marie-Christine Verpont; Michel Peuchmaur; Pierre Ronco; Renato C Monteiro; Elie Haddad
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

Review 9.  Nephrotic syndrome in childhood.

Authors:  Allison A Eddy; Jordan M Symons
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

10.  Focal segmental glomerular sclerosis, a type of intractable chronic glomerulonephritis, is a stem cell disorder.

Authors:  M Nishimura; J Toki; K Sugiura; F Hashimoto; T Tomita; H Fujishima; Y Hiramatsu; N Nishioka; N Nagata; Y Takahashi
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Immunology of idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Giorgia Corpetti; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2017-04-27       Impact factor: 3.714

2.  B cell phenotype in pediatric idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Rita Carsetti; Simona Cascioli; Jessica Serafinelli; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2018-09-28       Impact factor: 3.714

3.  Rituximab efficiency in children with steroid-dependent nephrotic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Marie-Alice Macher; Chantal Loirat; Valérie Guérin; Hervé Watier; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2010-03-18       Impact factor: 3.714

Review 4.  Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives.

Authors:  Valéry Elie; May Fakhoury; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2011-06-28       Impact factor: 3.714

5.  Toll-like receptor 3 expression and function in childhood idiopathic nephrotic syndrome.

Authors:  A Jamin; L Dehoux; C Dossier; M Fila; N Heming; R C Monteiro; G Deschênes
Journal:  Clin Exp Immunol       Date:  2015-09-30       Impact factor: 4.330

6.  Circulating plasmablasts in children with steroid-sensitive nephrotic syndrome.

Authors:  Federica Zotta; Marina Vivarelli; Rita Carsetti; Simona Cascioli; Francesco Emma; Manuela Colucci
Journal:  Pediatr Nephrol       Date:  2021-10-18       Impact factor: 3.714

Review 7.  Monoclonal antibodies for podocytopathies: rationale and clinical responses.

Authors:  Maddalena Marasà; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

Review 8.  Idiopathic nephrotic syndrome: the EBV hypothesis.

Authors:  Claire Dossier; Agnès Jamin; Georges Deschênes
Journal:  Pediatr Res       Date:  2016-09-28       Impact factor: 3.756

9.  B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.

Authors:  Manuela Colucci; Rita Carsetti; Simona Cascioli; Federica Casiraghi; Annalisa Perna; Lucilla Ravà; Barbara Ruggiero; Francesco Emma; Marina Vivarelli
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

10.  Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome.

Authors:  Anna Iharada; Kazunari Kaneko; Shoji Tsuji; Masafumi Hasui; Seiji Kanda; Toshimasa Nishiyama
Journal:  Pediatr Nephrol       Date:  2009-01-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.